Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 30, 2025 20:57 ET | Source: Direct Meds

Best Wegovy Alternative for 2026? FDA Approves Oral Semaglutide as Patients Evaluate Compounded Telehealth Access — Direct Meds Examined as Verification Case Study

Industry analysis examines how patients verify telehealth GLP-1 platforms after FDA oral semaglutide approval. Direct Meds included as case study.
December 26, 2025 23:34 ET | Source: Direct Meds

Direct Meds GLP-1 Medications Platform Maintains LegitScript Certification as New Year Weight Loss Interest Peaks Amid Compounding Regulatory Shifts

Analysis examines Direct Meds GLP-1 medications platform as LegitScript-certified telehealth option for compounded semaglutide and tirzepatide access.
December 26, 2025 18:48 ET | Source: MEDVI

Best Semaglutide Options for 2026: New Oral Wegovy Pill Approved by FDA as Patients Compare Injectable and Compounded Access Pathways

FDA approves oral Wegovy pill Dec 2025. Analysis compares FDA-approved injectable, oral, and compounded semaglutide access pathways for 2026.
December 18, 2025 19:15 ET | Source: LeanRx, Inc.

Is SkinnyRx the Best GLP-1 Vendor for 2026? Platform Offers Compounded Semaglutide in Three Forms Starting at $199/Month as New Year Weight Loss Season Approaches

SkinnyRx offers compounded semaglutide in 3 forms starting at $199/month through licensed providers as New Year weight loss demand approaches.
December 17, 2025 14:36 ET | Source: Levin Papantonio

Levin Papantonio - Federal Court Creates New MDL for Ozempic and Other GLP-1 Drugs Linked to Vision Loss (NAION)

U.S. JPML has created a new multidistrict litigation for lawsuits alleging that GLP-1 receptor agonist drugs cause NAION, a serious vision injury.
November 27, 2025 07:54 ET | Source: SNS Insider pvt ltd

Anti-Obesity Drugs Market Size to Reach $35.52 Billion by 2032, Driven by Advancements in Weight Management Therapies and Rising Obesity Prevalence | SNS Insider

Austin, Nov. 27, 2025 (GLOBE NEWSWIRE) -- Anti-Obesity Drugs Market Size & Growth Analysis: According to SNS Insider, the Anti-Obesity Drugs Market size was valued at $5.75 billion in 2024 and...
November 10, 2025 10:25 ET | Source: ACTG

ACTG Presents SLIM LIVER Findings at AASLD Liver Meeting Demonstrating Improvements in Biomarkers of Cardiovascular Risk among People Living with HIV and MASLD Who Receive Semaglutide

Treating people living with HIV and metabolic dysfunction-associated MASLD with semaglutide significantly improved biomarkers of cardiovascular risk.
November 04, 2025 19:22 ET | Source: XMD Wellness

RPX Enterprises and Xyngular Introduce XMD Wellness, a New Approach to Weight Loss and Wellness

New clinician-guided program blends medical science, microdosing, and 24/7 support to make advanced weight loss and wellness accessible nationwide.
October 30, 2025 08:00 ET | Source: Rani Therapeutics, LLC

Rani Therapeutics to Present Preclinical Data on Oral Delivery of Semaglutide via the RaniPill® Capsule at ObesityWeek® 2025

SAN JOSE, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral...
October 30, 2025 08:00 ET | Source: Biomea Fusion, Inc.

Biomea Fusion to Present Poster Presentations at ObesityWeek®2025

SAN CARLOS, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today announced that it will present...